GI Effects Comprehensive Stool Profile – Genova Diagnostics

£355.00

The GI Effects® Comprehensive Stool Profile is an advanced stool test that provides immediate, actionable clinical information for the management of gastrointestinal health. Utilising cutting-edge technologies and biomarkers, this test offers valuable insight into digestive function, intestinal inflammation, and the intestinal microbiome.

Categories: ,

The GI Effects® Comprehensive Stool Profile is an advanced stool test that provides immediate, actionable clinical information for the management of gastrointestinal health. Utilising cutting-edge technologies and biomarkers, this test offers valuable insight into digestive function, intestinal inflammation, and the intestinal microbiome.

The biomarkers from the GI Effects Comprehensive Profile are reported using the DIG framework, providing key clinical information for three main gastrointestinal functional areas:

● Digestion/Absorption:

○ Pancreatic Elastase-1 is a marker of exocrine pancreatic function.

○ Products of Protein Breakdown are markers of undigested protein reaching the colon.

○ Faecal Fat is a marker of fat breakdown and absorption.

● Inflammation/Immunology:

○ Calprotectin is a marker of neutrophil-driven inflammation. Produced in abundance at sites of inflammation, this biomarker has been proven clinically useful in differentiating between Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).3,4

○ Eosinophil Protein X is a marker of eosinophil-driven inflammation and allergic response.

○ Faecal Secretory IgA is a marker of gut secretory immunity and barrier function.

● Gut Microbiome:

○ Metabolic indicators, including short-chain fatty acids and beta-glucuronidase, demonstrate specific and vital metabolic functions performed by the microbiota.

○ Commensal Bacteria demonstrate the composition and relative abundance of gut organisms.

■ More than 95% of commensal gut organisms are anaerobic and are difficult to recover by traditional (aerobic) culture techniques.

■ GI Effects assesses a set of 24 genera/species that map to 7 major phyla.

○ Bacterial and mycology cultures demonstrate the presence of specific beneficial and pathological organisms.

○ Bacteria and mycology sensitivities are provided for pathogenic or potentially pathogenic organisms that have been cultured. The report includes effective prescriptive and natural agents.

○ Parasitology

■ GI Effects provides microscopic faecal specimen examination for ova and parasites (O&P), the gold standard of diagnosis for many parasites.

■ Enzyme immunoassay (EIA), widely recognised for its diagnostic utility in the detection of pathogenic antigens, is used for the identification of Cryptosporidium, Entamoeba histolytica, and Giardia lamblia.

■ Selection of a one-day or three-day sample collection is based on clinician’s clinical index of suspicion for parasitic infection. If there is no/low suspicion, a one-day sample will likely be adequate. For high suspicion, a three-day sample collection is optimal.

● Additional Biomarkers Available:

○ Campylobacter

○ Clostridium difficile

○ Escherichia coli

○ Faecal Lactoferrin

○ Helicobacter pylori

○ Macro Exam for Worms

○ Zonulin Family Peptide

○ KOH Preparation for Yeast

 

The shipment for this kit is £12 paid separately directly with the shipper as per the kit’s instructions.

View the kit at Genova Diagnostics

References

1. Marchesi J, et. al. The gut microbiota and host health: a new clinical frontier. Gut. 2016 Feb;65(2):330-9.

2. Clemente J, et. al. The impact of the gut microbiota on human health: an integrative review. Cell. 2012 Mar;148(6):1258-70.

3. Menees SB, et. al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015 Mar;110(3):444-54.

4. Dabritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J Gastroenterol. 2014 Jan;20(2):363-375.

5. Parsons K, et. al. Novel testing enhances irritable bowel syndrome medical management: the IMMINENT study. Glob Adv Health Med. 2014 May;3(3):25-32.

6. Goepp J, et. al. Frequency of abnormal fecal biomarkers in irritable bowel syndrome. Glob Adv Health Med. 2014 May;3(3):9-15.

 

If you have any questions please contact us

Reviews

There are no reviews yet.

Be the first to review “GI Effects Comprehensive Stool Profile – Genova Diagnostics”

Your email address will not be published. Required fields are marked *